Monte Rosa Therapeutics (GLUE) Common Equity (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Common Equity of $521.9 million for Q1 2026, up 89.68% year-over-year from $275.2 million in Q1 2025, and up 123.94% quarter-over-quarter from $233.1 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Common Equity (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $521.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 89.68% year-over-year to $521.9 million; the TTM figure through Mar 2026 stood at $521.9 million (up 89.68% YoY), while the FY2025 annual figure was $233.1 million, up 4.54% from the prior year.
- Common Equity for Q1 2026 stood at $521.9 million, up from $233.1 million in the prior quarter.
- The five-year high for Common Equity was $521.9 million in Q1 2026, with the low at $152.5 million in Q1 2024.
- The 5-year median for Common Equity is $243.7 million (2023), against an average of $256.5 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 637.61% in 2022, then sank 37.42% in 2024.
- Monte Rosa Therapeutics' Common Equity stood at $271.4 million in 2022, then sank by 33.96% to $179.2 million in 2023, then rose by 24.37% to $222.9 million in 2024, then grew by 4.54% to $233.1 million in 2025, then jumped by 123.94% to $521.9 million in 2026.
- Business Quant data shows GLUE's Common Equity at $521.9 million in Q1 2026, $233.1 million in Q4 2025, and $245.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 487.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 487.28 Mn |
| Mar 31, 2026 | 521.92 Mn |
| Dec 31, 2025 | 233.06 Mn |
| Sep 30, 2025 | 245.84 Mn |
| Jun 30, 2025 | 268.08 Mn |
| Mar 31, 2025 | 275.16 Mn |
| Dec 31, 2024 | 222.94 Mn |
| Sep 30, 2024 | 205.46 Mn |
| Jun 30, 2024 | 224.67 Mn |
| Mar 31, 2024 | 152.52 Mn |
| Dec 31, 2023 | 179.25 Mn |
| Sep 30, 2023 | 184.52 Mn |
| Jun 30, 2023 | 213.65 Mn |
| Mar 31, 2023 | 243.73 Mn |
| Dec 31, 2022 | 271.41 Mn |
| Sep 30, 2022 | 291.09 Mn |
| Jun 30, 2022 | 302.05 Mn |
| Mar 31, 2022 | 325.88 Mn |
| Dec 31, 2021 | 347.52 Mn |
| Sep 30, 2021 | 369.31 Mn |